Breast cancer, now the most prevalent cancer globally, includes a subtype known as triple‐negative breast cancer (TNBC), which lacks estrogen receptor and progesterone receptor expression, as well as human epidermal growth factor receptor 2 (HER2) amplification, comprising 24% of new breast tumors.[1] TNBC, marked by tumor heterogeneity and a lack of targeted hormone receptors, faces a grim prognosis and lacks effective therapies.[2] Its aggressive nature results in common early metastatic relapse and reduced survival rates. Here, ERBB2 is linked to cancer.